Improving treatment outcome in paediatric acute lymphoblastic leukaemia by minimal residual disease detection and pharmacokinetics [ 2011 - 2013 ]

Research Grant

Researchers: Prof Murray Norris (Principal investigator) ,  A/Pr Rosemary Sutton ,  Dr Luciano Dalla-Pozza ,  Prof Glenn Marshall ,  Prof Michelle Haber

Brief description The main objective of this project is to make substantial improvements in the treatment of patients with childhood leukaemia by greater use of molecular diagnostics to measure minimal residual disease (MRD) and pharmacokinetic testing to determine the effectiveness of a key chemotherapy drug (PEG-L-Asparaginase) in Australian patients enrolled on an international clinical trial which has been designed to reduce the incidence of both relapses and long term side-effects.

Funding Amount $AUD 609,759.15

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant